 | This is not a Wikipedia article: It is an individual user's work-in-progress page, and may be incomplete and/or unreliable. For guidance on developing this draft, see Wikipedia:So you made a userspace draft. Find sources: Google (books · news · scholar · free images · WP refs) · FENS · JSTOR · TWL |
PancreaSolve new article content ...
| Company type | Private |
|---|---|
| Industry | Biotechnology |
| Founded | 2015 |
| Headquarters | , |
Key people | V.A. Shiva Ayyadurai (Founder) |
Number of employees | 10 |
| Website | www |
PancreaSolve is an American biotechnology company, headquartered in Cambridge, Massachusetts. PancreaSolve was founded by V.A. Shiva Ayyadurai in 2015.
PancreaSolve has developed the world’s first computational platform for scalable integration of molecular pathway models. The platform provides an important contribution to the field of Systems Biology. Using PancreaSolve™, complex molecular pathway models have been tested and built for EGFR, nitric oxide and Interferon (IFN) pathways. Without PancreaSolve™, the integration of complex molecular pathway models is largely manual, time-consuming and in many cases, not possible.
PancreaSolve, Inc., uses its platform for drug development of vaccines, and cures for liver cancer and heart disease. The platform is also used for measuring the efficacy of health supplements and ‘nutraceuticals’. We provide opportunities for commercial companies such as biotech and pharmaceutical companies to work with us to use the PancreaSolve™ platform for supporting their internal drug development process.
PancreaSolve provides technology and services towards accelerating drug development using an integrative platform for quantitative modeling of complex molecular pathways. The platform uses in-silico modeling to bridge in-vitro testing with human clinical trials with the goal of eliminating animal experimentation. PancreaSolve™ is built on the foundation of Computational biology, a field that is in rapid transition from diagrammatic representation of pathways to quantitative and predictive mathematical models, which span time-scales, knowledge domains and spatial-scales. This transition is being accelerated by high-throughput experimentation which isolates reactions and their corresponding rate constants.
PancreaSolve also provides opportunities for commercial companies such as biotech and pharmaceutical companies to work with them to use the PancreaSolve platform for supporting their internal drug development process.
References
editExternal links
edit- http://www.pancreasolve.com Official website]